5-fluoro-3-methyl-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}-1-benzothiophene-2-sulphonamide | 1365037-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 5-fluoro-3-methyl-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}-1-benzothiophene-2-sulphonamide
• 英文别名: 5-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzothiophene-2-sulfonamide；5-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzothiophene-2-sulphonamide；5-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methyl-1-benzothiophene-2-sulfonamide
• CAS: 1365037-99-5
• 化学式: C₂₄H₂₅F₂N₃O₃S₂
• 分子量: 505.61
• InChiKey: RAYWFVBTQQRRAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  6-氟-3-(哌啶-4-基)苯并[D]异恶唑 在 水 、 potassium carbonate 、 三乙胺 、 甲胺 、 potassium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 123.0h， 生成 5-fluoro-3-methyl-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}-1-benzothiophene-2-sulphonamide
  参考文献：
  名称：

  Novel Arylsulfonamide Derivatives with 5-HT₆/5-HT₇ Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia

  摘要：

  In order to target behavioral and psychological symptoms of dementia (BPSD), we used molecular modeling-assisted design to obtain novel multifunctional arylsulfonamide derivatives that potently antagonize 5-HT6/7/2A and D-2 receptors, without interacting with M-1 receptors and hERG channels. In vitro studies confirmed their antagonism of 5-HT7/2A and D-2 receptors and weak interactions with key antitargets (M1R and hERG) associated with side effects. Marked 5-HT6 receptor affinities were also observed, notably for 6-fluoro-3-(piperidin-4-yl)-1,2-benzoxazole derivatives connected by a 3-4 unit alkyl linker with mono- or bicyclic, lipophilic arylsulfonamide moieties. N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulfonamide (72) was characterized in vitro on 14 targets and antitargets. It displayed dual blockade of 5-HT6 and D-2 receptors and negligible interactions at hERG and M-1 receptors. Unlike reference antipsychotics, 72 displayed marked antipsychotic and antidepressant activity in rats after oral administration, in the absence of cognitive or motor impairment. This profile is particularly attractive when targeting a fragile, elderly BPSD patient population.

  DOI：

  10.1021/jm401895u

文献信息

• [EN] ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES<br/>[FR] ARYLSULFAMIDES POUR LE TRAITEMENT DE MALADIES DU SNC
  申请人：ADAMED SP ZOO

  公开号：WO2012035123A1

  公开（公告）日：2012-03-22

  Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.

  化学式（I）的芳基磺酰胺衍生物及其药用盐。这些化合物可能对中枢神经系统的治疗和/或预防具有用处。
• ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES
  申请人：Kolaczkowski Marcin

  公开号：US20130172365A1

  公开（公告）日：2013-07-04

  Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.

  化学式（I）的芳基磺胺衍生物及其药用盐。这些化合物可能对中枢神经系统疾病的治疗和/或预防有用。
• US8822517B2
  申请人：——

  公开号：US8822517B2

  公开（公告）日：2014-09-02
• US9120767B2
  申请人：——

  公开号：US9120767B2

  公开（公告）日：2015-09-01
• Novel Arylsulfonamide Derivatives with 5-HT₆/5-HT₇ Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia
  作者：Marcin Kołaczkowski、Monika Marcinkowska、Adam Bucki、Maciej Pawłowski、Katarzyna Mitka、Jolanta Jaśkowska、Piotr Kowalski、Grzegorz Kazek、Agata Siwek、Anna Wasik、Anna Wesołowska、Paweł Mierzejewski、Przemyslaw Bienkowski

  DOI：10.1021/jm401895u

  日期：2014.6.12

  In order to target behavioral and psychological symptoms of dementia (BPSD), we used molecular modeling-assisted design to obtain novel multifunctional arylsulfonamide derivatives that potently antagonize 5-HT6/7/2A and D-2 receptors, without interacting with M-1 receptors and hERG channels. In vitro studies confirmed their antagonism of 5-HT7/2A and D-2 receptors and weak interactions with key antitargets (M1R and hERG) associated with side effects. Marked 5-HT6 receptor affinities were also observed, notably for 6-fluoro-3-(piperidin-4-yl)-1,2-benzoxazole derivatives connected by a 3-4 unit alkyl linker with mono- or bicyclic, lipophilic arylsulfonamide moieties. N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulfonamide (72) was characterized in vitro on 14 targets and antitargets. It displayed dual blockade of 5-HT6 and D-2 receptors and negligible interactions at hERG and M-1 receptors. Unlike reference antipsychotics, 72 displayed marked antipsychotic and antidepressant activity in rats after oral administration, in the absence of cognitive or motor impairment. This profile is particularly attractive when targeting a fragile, elderly BPSD patient population.